Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Compugen Ltd.

35 indications, side-by-side phase, drug & LoA

$2.04

0 (0%)

D 32Pipeline Score Richly Valued Biotech · Clinical
Market Cap
264.75 M
EPS
0.37
P/E Ratio
7.65 $
Value Trade
1.74 M
-5.08 %
Week
-2.44 %
1 Month
59.09 %
3 Month
84.21 %
6 Month
-66.71 %
5 Year
-72.77 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
206.98 K
52 Week Range
1.30 - 3.24
% held by Insiders
2.19 %
% held by Institutions
15.26 %
Enterprise Value
132.73 M
Total Shares
93.54 M
Short %
2.65 %
Float Shares
93.48 M
Company Description
Employees:75
https://www.cgen.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 1 data readout example
COM701 (anti-PVRIG antibody) relapsed platinum sensitive ovarian cancer
Phase 1
—
Biologics
Oncology
COM701 (anti-PVRIG antibody) relapsed platinum sensitive ovarian cancer
Phase 1
—
Biologics
Oncology
COM701 (anti-PVRIG antibody) relapsed platinum sensitive ovarian cancer
Phase 1
—
Biologics
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D32
Pipeline Score
$29M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.1x
rNPV / MCap
Top 37%
Micro Cap
(rank 571 of 905)
Percentile Rank
Compugen Ltd. faces pipeline headwinds (32/100), with $294M risk-adjusted pipeline value, led by COM701 in Advanced Cancer (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Dose escalation: COM902 monotherapy.
Small molecule		Advanced CancerPhase 1NCT0435424610% $98M COMPLETED 94 AVERAGE C (46) Apr 1, 2026MODERATE_RISKMEDIUM
Jun 12, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
COM701
relapsed platinum sensitive ovarian cancer
Phase 1
2025-07-21
COM701
relapsed platinum sensitive ovarian cancer
Phase 1
2025-07-21
COM701
relapsed platinum sensitive ovarian cancer
Phase 1
2025-07-21
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in CGEN
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CGEN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CGEN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CGEN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
CGEN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
CGEN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
2026-06-18 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Compugen Ltd. (CGEN) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How CGEN ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Ovarian Cancer #31 of 61 PHASE 1 COM701 + Normal Saline
MRK AZN LLY
$4.0B 0.8 FOLLOWER